Dr. Kathryn Kolibaba on R-CHOP and Bortezomib Combo in Diffuse Large B-Cell Lymphoma
Kathryn Kolibaba, MD, discusses results from the phase II trial dubbed Pyramid Trial. The open-label trial examined a combination of R-CHOP and bortezomib in patients with untreated non-germinal center B-cell-like subtype diffuse large cell lymphoma.
Kathryn Kolibaba, MD, hematologist, Compass Oncology, US Oncology Network, discusses results from the phase II trial dubbed Pyramid Trial (NCT00931918). The open-label trial examined a combination of R-CHOP and bortezomib in patients with untreated non-germinal center B-cell-like (non-GCB) subtype diffuse large cell lymphoma (DLBCL).
Kolibaba says it came as a surprise to researchers that the addition of bortezomib to R-CHOP did not produce a significant outcome. She said despite this, researchers still gathered important information about diagnostic criteria from across the United States that will allow for a quicker accrual for upcoming trials.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
